Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia

Hagop M. Kantarjian, Yun Su, Elias J. Jabbour, Helen Bhattacharyya, Eric Yan, Joseph C. Cappelleri, David I. Marks

Research output: Contribution to journal › Article › peer-review

39 Scopus citations

Fingerprint

Dive into the research topics of 'Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia'. Together they form a unique fingerprint.

Medicine & Life Sciences